Vamp2 Gene Synaptobrevin 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The VAMP2 (Vesicle-Associated Membrane Protein 2) gene encodes a critical synaptic vesicle protein essential for neurotransmitter release and synaptic vesicle fusion. VAMP2 is a member of the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment Protein Receptor) family and plays a central role in synaptic transmission, neuronal signaling, and membrane trafficking. Mutations in VAMP2 are associated with neurodevelopmental disorders, including autism spectrum disorder and epileptic encephalopathy.
This gene is involved in:
VAMP2 (Vesicle-Associated Membrane Protein 2), also known as Synaptobrevin-2, is a gene encoding a critical SNARE protein essential for synaptic vesicle fusion and neurotransmitter release. It plays a fundamental role in synaptic transmission and has been implicated in several neurodegenerative diseases.
| Property | Value |
|---|---|
| Gene Symbol | VAMP2 |
| Chromosomal Location | 17p13.1 |
| Protein | VAMP2 / Synaptobrevin-2 |
| Function | Synaptic vesicle fusion, neurotransmitter release |
| Related Diseases | Alzheimer's Disease, Parkinson's Disease, ALS |
VAMP2 is a small transmembrane protein (116 aa) that:
VAMP2 is a member of the SNAP-25 family with distinctive features:
The SNARE complex forms a four-helix bundle:
This complex undergoes zippering from N- to C-terminus, pulling the vesicle membrane to the plasma membrane for fusion.
VAMP2 is highly expressed in:
Expression patterns:
The formation of the SNARE complex follows a defined sequence:
The study of Vamp2 Gene Synaptobrevin 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
VAMP2 (Vesicle-Associated Membrane Protein 2), also known as Synaptobrevin-2, is a small transmembrane protein that plays a critical role in synaptic vesicle fusion. As a member of the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment Protein Receptor) complex, VAMP2 pairs with syntaxin-1 and SNAP-25 to form the minimal machinery required for neurotransmitter release.
The SNARE complex assembles in a zipper-like fashion, bringing the synaptic vesicle membrane (via VAMP2) into close proximity with the presynaptic plasma membrane (via syntaxin-1 and SNAP-25). This assembly drives membrane fusion and releases neurotransmitters into the synaptic cleft. The entire process is tightly regulated by complexins and synaptotagmin, calcium sensors that ensure rapid and synchronous release.
Alzheimer's Disease: VAMP2 is involved in synaptic vesicle cycling, and alterations in its function may contribute to synaptic dysfunction in AD. The protein interacts with amyloid-beta and may be affected by oligomeric forms of the peptide. Studies show reduced VAMP2 levels in AD brains, correlating with cognitive decline.
Parkinson's Disease: VAMP2 plays a role in dopaminergic neurotransmission, as vesicles containing dopamine require functional SNARE machinery for release. Mutations affecting SNARE complex formation may contribute to PD pathogenesis. The protein is also involved in alpha-synuclein aggregation pathways.
Huntington's Disease: VAMP2 function may be impaired in HD, contributing to synaptic dysfunction and neurotransmitter release deficits. The protein interacts with mutant huntingtin and may be part of the pathological inclusions.
Targeting VAMP2 or its interactions with other SNARE proteins could provide therapeutic approaches for neurodegenerative diseases. Botulinum neurotoxins (BoNTs) cleave VAMP2, temporarily blocking synaptic transmission - this mechanism is exploited clinically for dystonia and spasticity treatment.
Current research focuses on understanding how VAMP2 dysfunction contributes to neurodegenerative disease pathogenesis and developing small molecules that can modulate SNARE complex formation.
VAMP2 (Vesicle-Associated Membrane Protein 2), also known as Synaptobrevin-2, is a small transmembrane protein that plays a critical role in synaptic vesicle fusion. As a member of the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment Protein Receptor) complex, VAMP2 pairs with syntaxin-1 and SNAP-25 to form the minimal machinery required for neurotransmitter release.
The SNARE complex assembles in a zipper-like fashion, bringing the synaptic vesicle membrane (via VAMP2) into close proximity with the presynaptic plasma membrane (via syntaxin-1 and SNAP-25). This assembly drives membrane fusion and releases neurotransmitters into the synaptic cleft. The entire process is tightly regulated by complexins and synaptotagmin, calcium sensors that ensure rapid and synchronous release.
Alzheimer's Disease: VAMP2 is involved in synaptic vesicle cycling, and alterations in its function may contribute to synaptic dysfunction in AD. The protein interacts with amyloid-beta and may be affected by oligomeric forms of the peptide. Studies show reduced VAMP2 levels in AD brains, correlating with cognitive decline.
Parkinson's Disease: VAMP2 plays a role in dopaminergic neurotransmission, as vesicles containing dopamine require functional SNARE machinery for release. Mutations affecting SNARE complex formation may contribute to PD pathogenesis. The protein is also involved in alpha-synuclein aggregation pathways.
Huntington's Disease: VAMP2 function may be impaired in HD, contributing to synaptic dysfunction and neurotransmitter release deficits. The protein interacts with mutant huntingtin and may be part of the pathological inclusions.
Targeting VAMP2 or its interactions with other SNARE proteins could provide therapeutic approaches for neurodegenerative diseases. Botulinum neurotoxins (BoNTs) cleave VAMP2, temporarily blocking synaptic transmission - this mechanism is exploited clinically for dystonia and spasticity treatment.
Current research focuses on understanding how VAMP2 dysfunction contributes to neurodegenerative disease pathogenesis and developing small molecules that can modulate SNARE complex formation.